We synthesized several novel bifunctional alkylating derivatives of 3a-aza-cyclopenta [a]indene (BO-1012, BO-1005, BO-1099 and BO-1101 that are potent DNA interstrand crosslinking agents. In in vitro cytotoxicity assay, these compounds were more cytotoxic to multidrug-resistant (MDR) cells, such as KBvin10, KBtax50 and CEM/VBL, than their parental cells. Using a xenograft model, BO-1012, at a dose of 5 mg/kg, partially suppressed the growth of parental KB cells but completely suppressed the growth of KBvin10 cells in nude mice. In exploring the possible mechanism, we found that DNA double-strand break (DSB) repair activity in MDR cells, KBvin10 and CEM/VBL, was significantly reduced compared with their parental cells, KB and CEM. Reduced DSB repair activity in KBvin10 cells was likely due to a defect in nuclear translocation of DNA-dependent protein kinase (DNA-PK), a component of the non-homologous end-joining repair machinery. Furthermore, BO-1012-induced DNA-PK translocation from the cytosol into the nucleus in KB cells is associated with the activation of the Src/nuclear epidermal growth factor receptor (EGFR) cascade, which is defective in MDR cells. As knockdown of P-glycoprotein (P-gp) by siRNA reactivated the Src/nuclear EGFR cascade, DNA-PK translocation and DNA repair activity in MDR cells, overexpression of P-gp attenuates the activity of DNA DSB repair through suppression of Src/nuclear EGFR cascade. Therefore, DNA interstrand crosslinking agents may have potential therapeutic use against P-gp-overexpressing MDR cells.
INTRODUCTION
Multidrug resistance (MDR) is a key factor impeding the success of chemotherapy in cancer patients.
1,2 Emergence of MDR is often associated with overexpression of the MDR1 gene product, P-glycoprotein (P-gp).
3,4 P-gp is a transmembrane phosphoglycoprotein capable of transporting a variety of structurally and functionally diverse chemotherapeutic drugs, such as vinblastine (VBL), vincristine, doxorubicin and paclitaxel, leading to reduced intracellular drug concentration and cytotoxicity. 5 Clinically, overexpression of P-gp in tumor tissues is a prognostic indicator for poor response to chemotherapy and poor clinical outcome. 1, 3, 6 A variety of agents, including synthesized and natural MDR modulators, antibodies against MDR proteins, antisense oligonucleotides and ribozymes, have been developed to modify, modulate or reverse the P-gp-mediated MDR phenotype. 2, 7, 8 However, most of these compounds do not effectively overcome drug resistance at a clinically endurable level. Development of novel compounds to inhibit P-gp export activity or target alternative mechanisms sensitizing MDR cells to therapeutic agents remains a great challenge for cancer treatment. [9] [10] [11] In addition to P-gp overexpression, increased DNA repair activity is frequently associated with the resistance of cancer cells to DNA damage agents. 12, 13 DNA-dependent protein kinase (DNA-PK) has an essential role in the process of nonhomologous end-joining (NHEJ), a major pathway for the repair of DNA double-strand breaks (DSBs) in mammals. 14 Increased expression of DNA-PK prevents chemotherapy-treated cancer cells from undergoing apoptosis, 15 whereas cancer cells deficient in DNA-PK show increased sensitivity to ionizing radiation or chemotherapeutic agents. 16 Although activation of DNA-PK involves its phosphorylation and nuclear translocation, 17 the regulatory pathway of DNA-PK activation after drug treatment remains unclear. One possible molecular mechanism facilitating DNA-PK translocation from the cytoplasm into the nucleus is the Src kinase-mediated epidermal growth factor receptor (EGFR) translocation into nucleus. 18, 19 The proto-oncogene Src, which encodes the non-receptor tyrosine kinase Src, is strongly implicated in the development and progression of a variety of human cancers. [20] [21] [22] Src kinase has a fundamental role in the regulation of cell proliferation, migration, adhesion and tumor angiogenesis by directly interacting with a variety of signal transducers. 23, 24 Therefore, targeting Src offers a novel therapeutic intervention strategy to cancers. 25, 26 Following ionizing radiation, internalized EGFR is shuttled into the nucleus and facilitates DNA-PK-mediated repair. 19 Meanwhile, Src was reported to phosphorylate EGFR at residue Y845 and caveolin-1 at residue Y14, which causes them to form a complex and the subsequent internalization of EGFR into caveolae. 19 Nuclear EGFR also associates with DNA repair and drug resistance in human cancer cells treated with cisplatin. 27 Although the detailed mechanism remains to be elucidated, the Src/nuclear EGFR cascade has a crucial role in DNA repair activation. 1 We previously synthesized a novel series of DNA crosslinking agents, the bis(hydroxymethyl) of 3a-azacyclopenta[a]indene-1-yl and the bis(methylcarbamate) derivatives on the basis of mitomycin C (MMC) and bis(carbamates)-pyrrolizidines. 28 The anticancer mechanism of these agents was revealed by the induction of DNA interstrand crosslinks (ICLs) and DSBs. 28, 29 Most of the synthesized ICL agents were more or equally cytotoxic to MDR cells and VBL-and taxol-resistant CCRF-CEM cells as compared with the parental CCRF-CEM cells. 28, 30 Thus, the derivatives of 3a-azacyclopenta[a]indene may overcome the action of P-gp. We further observed that treatment of human large cell lung carcinoma H460 cells with BO-1012, a derivative of 3a-azacyclopenta[a]indene, significantly activated Rad51 and DNA-PK, protein components involved in the homologous recombination repair and NHEJ pathways, respectively. 29 Therefore, combining BO-1012 with arsenic trioxide, which may function as a DNA repair inhibitor, synergistically suppresses tumor growth in vitro and in nude mice transplanted with the inherently resistant H460 tumor and the acquired cisplatin-resistant bladder transitional carcinoma NTUB1/P. 29 These results prompted us to ask whether the derivatives of 3a-azacyclopenta[a]indene could suppress the growth of MDR cells in xenograft models, whether DNA repair is defective in MDR cells, and whether and how P-gp overexpression has a role in attenuating DNA repair activity.
RESULTS
MDR cancer cells are susceptible to DNA interstrand crosslinking agents MDR with overexpression of P-gp is the most common mechanism of clinically relevant resistance to cancer therapy. 2 To conquer MDR cells is of essential importance for the success of cancer therapy. Therefore, we evaluated the cytotoxicity of a series of 3a-azacyclopenta[a]indene derivatives (BO-1012, BO-1005, BO-1099 and BO-1101), which mainly cause DNA ICLs, 28 toward MDR cancer cells with P-gp overexpression, including KBvin10, KBtax50 and CEM/VBL cells. KBvin10 and KBtax50 cells were derived from KB cells, 31 while CEM/VBL cells were derived from the human T-lymphoblastic leukemia cell line, CEM. 32 As shown in Table 1 , the resistance factors (RF) of KBvin10, KBtax50 and CEM/VBL cells to vincristine were 160.3, 381 and 300.8, respectively, while the RF values of KBvin10 and KBtax50 cells to paclitaxel were 467 and 33.2, respectively. These results confirmed the cross-resistance of these three MDR cell lines to vincristine and paclitaxel. However, these MDR cells were equally or more susceptible to novel 3a-azacyclopenta[a]indene derivatives, BO-1012, BO-1005, BO-1099 and BO-1101, and clinically used DNA crosslinking agents, such as MMC, melphalan and cisplatin ( 29 Therefore, BO-1012 was chosen for further study to evaluate its activity against MDR cancers in xenograft animal models. Nude mice bearing KB, KBtax50 or KBvin10 xenografts were treated with vehicle, vincristine (1 mg/kg, Q2D for three times), and BO-1012 (2.5 or 5 mg/kg, Q2D for five times) via intravenous injection. As shown in Figure 1a , vincristine significantly suppressed the growth of parental KB cells in nude mice but showed no inhibitory effect to KBtax50 and KBvin10 cells at the same dose (Figures 1b and c) . Although BO-1012 was much less effective than vincristine at inhibiting the growth of KB cells (Figure 1a) , it effectively and dose-dependently suppressed the growth of KBtax50 and KBvin10 in nude mice (Figures 1b and c) . Remarkably, the growth of KBtax50 xenografts in nude mice were delayed by BO-1012 at the dose of 5 mg/kg (88.6% tumor suppression on day 15) (Figure 1b) . However, at the same dose, BO-1012 induced KBvin10 tumors with complete remission for over 89 days without tumor relapse (Figure 1c) . The body weight loss in tumor-bearing mice treated with various doses of BO-1012 was 8% less than at the beginning (Figures 1a-c, right ), but this reverted and gradually increased later. As the body weight changes were commonly used to evaluate systemic toxicity induced by treatment, our results imply that BO-1012 did not cause obvious systemic toxicity at its effective dose against MDR tumors.
MDR cancer cells are defective in repair of BO-1012-induced DNA damage As overexpression of P-gp in MDR cells is a well-known mechanism responsible for cross-resistance to several chemotherapeutic drugs, 33 experiments were conducted to understand the roles of P-gp on the cytotoxic effect of BO-1012. As shown in Figure 2a , both KBtax50 and KBvin10 MDR cells have remarkably higher expression levels of P-gp as compared with parental KB cells, whereas the expression level of P-gp in KBvin10 cells was significantly higher than that in KBtax50 cells. In addition, P-gp expression was further enhanced in KBvin10 or CEM/VBL cells with BO-1012 treatment (Figure 2b ). However, pretreatment of cells with Elacridar (Figure 2d ), a P-gp pump blocker, for 1 h and followed by cotreatment with BO-1012 did not enhance the cell-killing activity of BO-1012 in either KB or KBvin10 cells, whereas Elacridar treatment remarkably reduced the value IC 50 to vincristine in KBvin10 cells (Figure 2c) . Similarly, verapamil, a P-gp efflux competitor, could not modulate the cytotoxicity of BO-1012 (Supplementary Figure 1) . These results indicated that the pumping activity of P-gp was unlikely related to the cytotoxic effects of BO-1012.
As BO-1012 induces DNA ICLs and DSBs, 28, 29 we performed experiments to investigate whether the overexpression of P-gp disturbs the repair of DNA lesions induced by BO-1012. (Figure 2e ). Immunofluorescence staining using a primary antibody against gH2AX consistently demonstrated that BO-1012-induced gH2AX in the nuclei of KB cells was significantly reduced in a time-dependent manner, whereas the decline of gH2AX in BO-1012-treated KBvin10 cells was insignificant after a 72-h incubation ( Figure 2f ). We further adopted the modified comet assay 29 to compare the repair activity of DNA ICLs in KB and KBvin10 cells.
As shown in Supplementary Figure 3 , BO-1012-induced DNA ICLs was more efficiently reduced in KB cells than in KBvin10 cells. Taken together, the activity of repairing BO-1012-induced DNA damage in MDR cells is inversely associated with the expression level of P-gp. As such, KBvin10 cells with the highest P-gp expression showed the least DSB repair activity among these three cell lines.
BO-1012 induces G2/M arrest in KB, KBvin10 and KBtax50 cells As DNA damage usually results in perturbation of cell cycle progression, 34, 35 we assessed the effects of BO-1012 on cell cycle progression in KB, KBvin10 and KBtax50 cells. After treatment of three cell lines with 80 mM BO-1012 for 1 h and subsequent incubation with drug-free medium for 24-72 h, the cell cycle distribution was analyzed by flow cytometry. insignificant in KBvin10 cells. Taken together, BO-1012-induced cytotoxicity and cell cycle perturbation among these three cell lines are consistently associated with DNA repair activity, which inversely correlates with P-gp levels.
The DNA-PK-associated repair pathway was diminished in MDR cancer cells BO-1012-induced DNA damage might activate DNA-PK and Rad51, components of the repair machineries involved in NHEJ and homologous recombination repair, respectively, in human lung cancer cells. 29 Therefore, we examined the effects of BO-1012 on DNA-PK and Rad51-associated DNA DSB repair pathways in KB and KBvin10 cells. As shown in Supplementary Figure 4a , BO-1012 treatment induced significant and approximately equal amounts of Rad51 protein in both KB and KBvin10 cells. In addition, the nuclear translocation of Rad51 was similar between BO-1012-treated KB and KBvin10 cells (Supplementary Figure 4b) . These results indicate that Rad51-associated homologous recombination repair pathways may be similarly activated by BO-1012 in KB and KBvin10 cells. Intriguingly, our immunofluorescence staining results showed that BO-1012 treatment induced DNA-PK translocation from the cytosol into the nuclei in KB cells but significantly suppressed that in KBvin10 cells (Figure 4a) . Similarly, by immunoblotting assay, we observed increased DNA-PK in nuclear extracts prepared from BO-1012-treated KB cells as compared with untreated cells, whereas DNA-PK in nuclei of BO-1012-treated KBvin10 cells was lower than that in untreated KBvin10 cells (Figure 4b) . Furthermore, when the expression of DNA-PK in KB cells was silenced by siRNA, the decline in BO-1012-induced gH2AX-positive cell was inhibited (Figure 4c left) . These results supported the involvement of DNA-PK in BO-1012-triggered DSB repair in KB cells. On the other hand, knockdown of DNA-PK did not further affect the repair of BO-1012-induced DSBs in KBvin10 cells (Figure 4c right) , confirming the lack of DNA-PK activation in BO-1012-treated KBvin10 cells. Consistently, we observed that the IC 50 value of BO-1012 in KB cells was significantly reduced by DNA-PK inhibitor, NU7441 (Figure 4d ). The attenuated DNA-PK in MDR cells was confirmed by their susceptibility to ionizing irradiation. As shown in Figure 4e , KBvin10 cells were more sensitive to X-ray irradiation than the parental KB cells. Thus, DNA-PK-associated DSB repair is abated in MDR cancer cells.
BO-1012 fails to activate Src/nuclear EGFR pathway in MDR cancer cells Src kinase-mediated EGFR activation is stress specific and results in nuclear transport of EGFR. 19, 36 Moreover, nuclear EGFR interacts with DNA-PK and further involves in the activation of kinase activity, which is essential for NHEJ. 36 To investigate whether the Src/nuclear EGFR cascade serves as a mechanism for BO-1012-induced DNA-PK repair, we assessed DNA-PK, Src and EGFR activities in KB and KBvin10 cells treated with BO-1012. As shown in Figure 5a , BO-1012 substantially induced Src activation by increasing Src protein expression and its phosphorylated product in KB and CEM parental cells, but not in their MDR variants. In addition, BO-1012 did not modulate the expression levels of EGFR (Figure 5b ) in either KB or KBvin10 cells, whereas BO-1012 significantly induced EGFR translocation into nuclei in KB parental cells, but not in KBvin10 cells (Figure 5b) . Treatment with the Srcspecific inhibitor, PP2, significantly inhibited BO-1012-triggered EGFR nuclear translocation in both KB and CEM parental cells (Figure 5c ). Using immunofluorescence staining, we also found that PP2 treatment suppressed BO-1012-induced nuclear translocation of DNA-PK in KB parental cells (Figure 5d ). Furthermore, PP2 treatment enhanced the susceptibility of BO-1012 to both parental KB and CEM cells (Supplementary Figure 5a) . Thus, blockage of Src activation prevents nuclear transport of EGFR and DNA-PK resulting in increased sensitivity of KB and CEM cells to BO-1012. Therefore, DNA damage induced by BO-1012 may be mediated by the Src/nuclear EGFR cascade to activate DNA-PK in parental KB and CEM cells, whereas activation of the Src/nuclear EGFR cascade is defective in MDR cells.
P-gp overexpression suppresses BO-1012-induced activation of the Src/nuclear EGFR-DNA-PK cascade As MDR cells with P-gp overexpression failed to repair DSB and thus were more susceptible to BO-1012 than their parental cells, whether P-gp overexpression hinders the activation of the DSB repair pathway is a question warranting our investigation. Therefore, P-gp siRNA were used to suppress expression of P-gp (Figure 6a ). The enhanced sensitivity to vincristine in P-gp silenced MDR cells was confirmed and shown in Supplementary Figure 5b .
With the aid of western blotting, we confirmed that treatment with BO-1012 did not activate Src and EGFR in KBvin10 and CEM/ VBL cells, whereas knockdown of P-gp resulted in the activation of Src and then nuclear translocation of EGFR in BO-1012-treated KBvin10 and CEM/VBL MDR cells (Figure 6a ). Moreover, knockdown of P-gp reactivated the nuclear translocation of DNA-PK in BO-1012-treated KBvin10 MDR cells, which could be further suppressed by PP2 ( Figure 6b ). As shown in Figure 6c , transfection of P-gp siRNA into MDR cells resulted in a significant decrease of gH2AX-positive cells at 72 h, whereas the level of BO-1012-induced gH2AX-positive cells in KBvin10 and CEM/VBL cells remained the same. Furthermore, the rate of decline in gH2AX-positive cells in P-gp silenced MDR cells was similar to that in the parental counterpart (Figure 6c ), indicating that overexpression of P-gp in MDR cells disturbs DSB repair. We further assessed the cytotoxic effect of BO-1012 in cells transfecting with the P-gp siRNA and DNA-PK siRNA. As shown in Figure 6d , inhibition of DNA-PK reduced the IC 50 values of BO-1012 in KB and CEM cells, whereas the IC 50 values of BO-1012 in KBvin10 and CEM/VBL were increased when P-gp expression was knocked down. Thus, P-gp overexpression contributes to the repression of Src/nuclear EFGRmediated DSB repair in MDR cells and hence increases their sensitivity to BO-1012. 28 suppressed the growth of MDR cells in xenograft mouse models more effectively than parental cells. The susceptibility of MDR cells to BO-1012 is likely due to a defect in the activation of DNA-PK, a core component of NHEJ, by overexpressed P-gp. First, we found that BO-1012-induced DSBs and G2/M arrest are decreased and DNA-PK nuclear translocation is significantly increased in parental cells. Thus, the lesions induced by BO-1012 might activate the DNA-PK-mediated repair pathway to decrease DSBs and avert the G2/M arrest. Second, the repair of BO-1012-induced DSB and G2/M arrest in MDR cells were inversely associated with the levels of P-gp. Third, although expression of Rad51, a core component of homologous recombination repair, remained normal in MDR cells, nuclear translocation of DNA-PK was suppressed in MDR cells. Fourth, MDR cells were more sensitive to ionizing radiation than their parental cells, supporting the attenuated DNA-PK activity in MDR cells. Therefore, P-gp overexpression impedes the activation of DNA-PK and consequently attenuates DSB repair, thereby sensitizing them to BO-1012 or other DNA ICL agents.
A common mechanism of MDR is the active export of drug by the overexpression of P-gp in the cell membrane. 33 P-gp, a 170-kDa transmembrane glycoprotein encoded by the ABCB1 (MDR1) gene, mediates resistance to several anticancer agents. 37, 38 How P-gp interferes with DNA-PK nuclear translocation is entirely unknown. Using inhibitor and siRNA approaches, our current results revealed that injuries induced by BO-1012 were mediated through the Src/nuclear EGFR cascade to activate DNA-PK nuclear translocation and lesion repair in parental cells. In MDR cells, P-gp overexpression attenuated BO-1012-induced Src/nuclear EGFR cascade activation and DNA-PK nuclear translocation. Actually, EGFR has an essential role in DNA-PK-mediated repair; EGFR translocates into the nucleus, interacts with DNA-PK and activates its repair activity in response to ionizing radiation or cisplatin treatment. 27, 39 In addition, Src, an upstream kinase of EGFR, stimulates radiation-associated EGFR and caveolin 1 activation, and increases nuclear transport of EGFR. 19, 36 It is likely that P-gp overexpression suppresses DNA damage-activated Src/nuclear EGFR cascade, which has a crucial role in the nuclear translocation of DNA-PK. How P-gp suppresses the DNA damage-activated Src/nuclear EGFR cascade is still unknown. Although P-gp is known to extrude a variety of drugs through active exportation, 33 P-gp was also shown to inhibit the expression of an oncogene pokemon through direct binding to its prompter region. 40 Whether P-gp is a direct or indirect repressor for Src expression warrants further investigation. Src, a non-receptor tyrosine kinase encoded by the SRC gene, 41 is transiently activated during multiple cellular events. 42 However, Src is overexpressed and/or hyperactivated in a large variety of cancer cells and is probably a strong promoting factor for cancer development. 43 EGFR nuclear translocation is highly associated with its phosphorylation by Src. 19, 36 Actually, EGFR overexpression is a manifestation of human cancer cells with increased resistance to chemo-and radiotherapy. 44 The involvement of EGFR in DNA repair activation has been well reported. EGFR physically interacts with DNA-PK. 45 Anti-EGFR monoclonal antibodies suppress EGFR activity resulting in reduced nuclear DNA-PK protein and kinase activity. 46 EGFR activation is not only associated with DNA-PK nuclear translocation but also DSB rejoining. 47 Upon treatment with anticancer drugs, transmembrane EGFR, together with its partners, translocates into the nucleus to facilitate gene transcription and DNA repair. 36, 48, 49 Therefore, targeting Src and EGFR pathways is considered a new clue to treat cancer. 50, 51 In this The levels of EGFR in whole cell extract (WCE) and nuclear extract (NE) were determined by western blot analysis. b-Actin and Lamin B1 were included as loading controls for WCE and NE, respectively. (c) Inhibition of EGFR nuclear translocation by a Src inhibitor. KB and CEM parental cells were pretreated with 1 mM PP2, a Src inhibitor, for 30 min and then cotreated with 80 and 5 mM BO-1012, respectively, for 1 h, followed by incubation with 1 mM PP2 for 24 h. After treatment, the EGFR levels in NE were determined by western blot analysis.
(d) Inhibition of DNA-PK nuclear translocation by a Src inhibitor. KB cells were treated with PP2 and BO-1012 according to the protocol described in (c). After treatment, DNA-PK (green) localization was determined by immunofluorescence staining. Nuclei were counterstained with DAPI (blue). Left, representative images. Right, the relative fluorescent intensity of nuclear DNA-PK (nuclear DNA-PK/total DNA-PK). The relative intensity of nuclear DNA-PK and total DNA-PK of 50 cells in each treatment was determined using fluorescence microscopy. *Po0.05 as compared to BO-1012 alone.
study, P-gp overexpression attenuated the Src/nuclear EGFR cascade. Therefore, exploring the detailed mechanism by which P-gp suppresses Src/nuclear EGFR activation may provide new clues for cancer therapy. Reversing MDR is a key to overcoming drug resistance in modern cancer therapy. Numerous MDR-reversing agents have been developed but failed during clinical trials for their toxicity in vital organs. 8, 9 Developing a means to inhibit P-gp/MDR is the next generation of cancer therapy. 7, 9, 11, 52 An early study has revealed that Chinese hamster ovary (CHO) cells that acquired P-gp/MDR by exposure to one agent, such as paclitaxel and VBL, gained increased sensitivity to an alternate agent, such as bleomycin or cisplatin, known as collateral sensitivity. 53 Similarly, cancer cell lines with acquired MDR or ectopic overexpression of P-gp have increased sensitivity to a variety of anticancer agents. 11, 54, 55 Intriguingly, MDR unrelated cellular alterations, such as changes in GLUT1 expression, have been found to lead to collateral sensitivity to 2-D-deoxy-glucose in MDR cells. 56, 57 In this study, DNA repair activation in MDR cells was defective. Therefore, MDR cells are more or equally susceptible to DNA ICL agents, which may be considered as potential therapeutic drugs against cancers with an MDR phenotype.
BO-1012 and it derivatives were synthesized based on the structure of MMC (Supplementary Figure 6 ; Table 1 ). However, the RF values of MMC in KBvin10, KBtax50 and CEM/VBL were more than 1.5 (1.5, 1.7 and 3.7, respectively), whereas those of BO-1012 were less than 0.8 (0.8, 0.7 and 0.6, respectively). In addition, P-gpoverexpressing cells were cross-resistant to adriamycin and mitomycin, while blockade of P-gp by shRNA decreased resistance to these drugs, 10 implicating that these compounds may be substrates of P-gp. However, P-gp pump blockers failed to enhance BO-1012-induced cytotoxicity in either parental or MDR cells, indicating that P-gp protein expression levels were more promising for its attenuation of DNA repair activity than its pump function. In addition, BO-1012 induced much higher levels of DNA ICLs than clinically used chemotherapeutic agents, melphalan and thiotepa. Consequently, BO-1012 triggered significant DSBs and cell death. 29 Thus, BO-1012 may be considered as is a promising therapeutic agent for future development to treat MDR cancer cells. Effect of P-gp silencing and Src inhibition on DNA-PK nuclear translocation. After P-gp was silenced, KBvin10 cells were treated with PP2 and BO-1012 as described in Figure 5c . Afterward, DNA-PK (green) was visualized by immunofluorescence staining. Nuclei were counterstained with DAPI (blue). Top, representative images; bottom, the relative fluorescence intensity of nuclear DNA-PK was determined as described in Figure 5d ; *Po0.05 as compared to each BO-1012-untreated group. In this study, MDR cells, which were cross-resistant to several clinical chemotherapeutic drugs, were defective in DNA-PKmediated repair resulting in increased sensitivity to the novel DNA crosslinking agent, BO-1012. The defect in DNA-PK-mediated repair in MDR cells is likely due to the inhibitory effect of overexpressed P-gp on the Src/nuclear EGFR cascade, which has a crucial role in the nuclear translocation of DNA-PK and repair of DSB. DNA ICL agents might be potential therapeutic drugs for the treatment of cancer patients with MDR/P-gp overexpression. CCRF-CEM (human lymphoblastic leukemia) and the VBL-resistant CEM/ VBL cell lines were obtained from Dr L Nutter (Institute of Biomedical Sciences, Academia Sinica, Taiwan). 32 All cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics, and incubated at 37 1C in a humidified atmosphere with 5% CO 2 . KBvin10 and KBtax50 were maintained in RPMI 1640 supplemented with 10 nM vincristine and 50 nM paclitaxel, respectively.
MATERIALS AND METHODS

Cytotoxicity assay
Cytotoxicity to various compounds was assessed using alamarBlue (AbD Serotec, Oxford, UK), which only stains viable cells by a reducing reaction in mitochondria. In brief, 3000-7000 cells were seeded in each well of 96-well plates and incubated at 37 1C overnight before drug treatment. After a 72-h drug treatment, alamarBlue solution was added to each well at a 1:10 dilution. The plates were further incubated at 37 1C in 5% CO 2 for 6 h. Measurement of cell viability was assessed by absorbance at 570/600 nm using an automatic enzyme-linked immunosorbent assay plate reader (Molecular Devices, Union City, CA, USA). The IC 50 values for each drug were determined from dose-effect relationship at six or seven concentrations using CompuSyn software (version 1.0.1; CompuSyn, Inc., Paramus, NJ, USA) by Chou and Martin based on the median-effect principle and plot. 58 Colony-forming assay Cytotoxicity of KB and KBvin10 cells to ionizing irradiation was analyzed by colony-forming assay. In brief, the logarithmically growing KB and KBvin10 cells were irradiated with X-ray at various doses. Afterward, appropriate cell numbers were seeded into six-well plates and then incubated for 10 days to allow single colony formation. At the end of incubation, the plates were washed twice with phosphate-buffer saline (PBS) and stained with a 10% Giemsa solution. 59 The number of colonies was counted under a dissection microscope.
Animal studies
Animal care was approved by and followed the guidelines of the Academia Sinica Institutional Animal Care and Utilization Committee. Six-week-old male BALB/c nude mice were obtained from the National Laboratory Animal Center (Taipei, Taiwan). The animals were housed in a specific pathogen-free environment under controlled conditions of light and humidity and were given sterilized food and water ad libitum. They were allowed to acclimate for 48 h after shipment and before tumor inoculation. KB (1 Â 10 7 cells), KBvin10 (1 Â 10 7 cells) or KBtax50 (1 Â 10 7 cells) cells in 100 ml of PBS (pH 7.4) were inoculated subcutaneously into the hind limbs of mice. When the resulting tumors reached 80-100 mm 3 in volume, mice were randomly assigned to different treatment groups. BO-1012 solution was prepared in 20% DMSO and 15% Tween-80 in 0.9% saline; vincristine was dissolved in ddH 2 O and diluted in 0.9% saline before injection. To monitor tumor formation, the longest and shortest diameters of the tumors were measured using calipers. Tumor volume was calculated according to the following formula: tumor volume ¼ (length Â width 2 )/2. Mouse body weight was measured and used as an indicator of the systemic toxicity of the treatment.
Western blot analysis P-gp, DNA-PKcs, EGFR, pSrc, Src and Rad51 were analyzed by western blotting as described previously. 60 Nuclei were isolated from KB, KBvin10, CEM and CEM/VBL cells using a Nuclei EZ Prep Nuclei Isolation Kit (Sigma, St Louis, MO, USA).
Immunofluorescence staining Cells were cultured on slides. To visualize gH2AX or DNA-PK, cells were washed with cold PBS and fixed with 100% ice-cold methanol for 30 min. Slides were washed with PBS twice and incubated with anti-gH2AX antibody for 2 h at room temperature or with DNA-PK antibody for 16 h at 4 1C followed by Alexa Fluor 488-conjugated secondary antibodies (Molecular Probes, Eugene, OR, USA) and DAPI. After mounting with 50% glycerol, slides were subjected to imaging on a laser scanning confocal microscope (LSM 510, Carl Zeiss MicroImaging Inc., Thornwood, NY, USA). The relative intensity of DNA-PK in nuclei to whole cell was determined using Carl Zeiss Laser Scanning Microscope LSM510 version 3.5 software (Carl Zeiss MicroImaging Inc.).
Flow cytometry
The levels of phosphorylated histone H2AX (gH2AX) and cell cycle progression in cells treated with BO-1012 were analyzed using flow cytometry as previously described. 30, 61 In brief, at the end of treatment, cells were fixed with 70% ethanol for 16 h, washed with PBS and incubated with mouse anti-gH2AX antibody (Upstate Biotechnology, Waltham, MA, USA) for 2 h, followed by FITC-conjugated goat anti-mouse (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) for 30 min. Cells were counterstained with propidium iodide (PI; 4 mg/ml) in PBS containing 0.1 mg/ml RNase A and analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). gH2AX-positive cells were gated and estimated from a total of 10 000 cells by subtracting the cells with the same signal intensity as control histograms. For cell cycle analysis, the cells were trypsinized, fixed with ice-cold 70% ethanol at least 30 min, stained with 4 mg/ml PI in PBS containing 1% Triton X-100 and 0.1 mg/ml RNase A, and then subjected to flow cytometric analysis. The cell cycle phase distribution was analyzed using ModFit LT 2.0 software (Verity Software House, Topsham, ME, USA).
Modified comet assay
The repair of intracellular DNA ICLs was analyzed using modified comet assay as previously described. 28 In brief, KB and KBvin10 cells were treated with BO-1012 for 1 h, followed by washing with PBS and incubating in fresh medium for 24, 48 and 72 h. At the end of incubation, the cells were irradiated with X-ray at 20 Gy and immediately subjected to the single cell alkaline gel electrophoresis. Percentage of ICLs in cells after incubation was calculated by the percentage of decrease in tail moment of cells irradiated with 20 Gy alone.
RNA interference
The siRNA sequence targeting DNA-PKcs was 5 0 -GAUCGCACCUUACUCU GUUdTdT-3 0 . 62 Double stranded DNA-PK siRNA was obtained from Prisma Biotech (Taipei, Taiwan). P-glycoprotein (ABCB1) siRNA was purchased from Invitrogen Life Technologies, Inc. (Carlsbad, CA, USA). A doublestranded RNA (5 0 -CGUACGCGGAAUACUUCGATT-3 0 ) targeting the luciferase gene was used as a negative control. Transfection of siRNA into the cells was performed as previously described. 40 In brief, 5 Â 10 5 cells in the exponential phase of growth were plated in 60 mm dishes, incubated for 24 h and transfected with siRNA using Lipofectamine 2000 reagent and OPTI-MEM I reduced serum medium (Invitrogen, Grand Island, NY, USA). At 24 h after transfection, the cells were incubated in fresh medium for 24 h, and cellular expression of DNA-PK and P-gp was determined by western blot analysis.
Statistical analysis
All data represent at least three independent experiments. The data are presented as mean±s.e. The statistical significance of differences was assessed using the Student's t-test.
